Ipratropium Bromide — Veterinary Vademecum Drug Reference

Dosage & Administration Guidelines

Species	Route	Dose	Frequency	Duration & Clinical Notes
Dog	Inhalation (via metered-dose inhaler with spacer)	1-2 puffs (each puff delivers 20-40 mcg) every 8-12 hours	q8-12h	Duration: As needed for clinical signs; often used long-term in chronic conditions Notes: Use with a spacer device and mask. Shake well before use. Monitor for cough or bronchospasm.
Cat	Inhalation (via metered-dose inhaler with spacer)	1-2 puffs (each puff delivers 20-40 mcg) every 8-12 hours	q8-12h	Duration: As needed; often used in combination with inhaled corticosteroids Notes: Use with a feline-specific mask and spacer. Administer after bronchodilator if using both.
Horse	Inhalation (nebulization)	0.5-1.5 mg per horse (diluted in saline) every 6-8 hours	q6-8h	Duration: For acute exacerbations; may be used as needed Notes: Nebulize with a suitable equine nebulizer. Monitor for tachycardia.
Cattle	Inhalation (nebulization)	0.02-0.05 mg/kg (estimated) every 8-12 hours	q8-12h	Duration: Short-term for bronchospasm Notes: Off-label use; limited data. Use with caution.
Small Ruminants	Inhalation (nebulization)	0.02-0.05 mg/kg (estimated) every 8-12 hours	q8-12h	Duration: Short-term Notes: Off-label use; limited data.
Rabbit	Inhalation (nebulization)	0.02-0.05 mg/kg (estimated) every 8-12 hours	q8-12h	Duration: Short-term Notes: Off-label use; limited data.

Clinical Indications & Species Uses

General Indications

Bronchodilation in conditions with reversible bronchospasm
Adjunct to beta-2 agonists in acute asthma exacerbations

Dog (Canine)

Adjunct therapy for bronchoconstriction associated with chronic bronchitis
Asthma
Feline lower airway disease (though more common in cats, can be used in dogs)
Reduction of airway secretions in chronic respiratory disease

Cat (Feline)

Feline bronchial disease (asthma)
Chronic bronchitis
Adjunct to bronchodilator therapy (e.g., beta-agonists)

Horse (Equine)

Recurrent airway obstruction (heaves)
Inflammatory airway disease
Exercise-induced pulmonary hemorrhage (as adjunct)

Pharmacology & Mechanism of Action

Drug Class: Anticholinergic / Bronchodilator | Pharmacological Group: Quaternary ammonium antimuscarinic agent

Mechanism of Action: Ipratropium bromide is a synthetic quaternary ammonium compound that acts as a competitive antagonist at muscarinic acetylcholine receptors. By blocking the action of acetylcholine at these receptors, it inhibits cholinergic-mediated bronchoconstriction and reduces airway mucus secretion. Its quaternary structure limits its absorption across lipid membranes, resulting in a primarily topical effect on the airways when inhaled, with minimal systemic anticholinergic effects.

Pharmacodynamics: In the respiratory tract, ipratropium bromide produces bronchodilation by relaxing smooth muscle in the large and small airways. It also reduces vagal tone, which can decrease bronchial hyperreactivity. The onset of action is typically within 15-30 minutes after inhalation, with peak effects at 1-2 hours and a duration of 4-6 hours. It does not suppress inflammatory responses and is not effective as a sole therapy for acute severe bronchospasm but is useful as an adjunct to beta-agonists.

⚡ Pharmacokinetics Summary

Absorption: When administered via inhalation, systemic absorption is minimal due to the quaternary ammonium structure and poor lipid solubility. The majority of the dose is either deposited in the oropharynx and swallowed or remains in the airways. Oral bioavailability is negligible (1-2%).

Distribution: The drug is primarily distributed to the lungs after inhalation. Systemic distribution is limited due to poor absorption. It does not cross the blood-brain barrier significantly.

Metabolism: Ipratropium is minimally metabolized. A small fraction is hydrolyzed to inactive tropane alkaloid derivatives, possibly by esterases in the liver or plasma.

Excretion: The absorbed fraction is excreted primarily in the urine, with a small amount in feces. The elimination half-life is approximately 2 hours after intravenous administration, but the clinical effect lasts longer due to receptor binding.

Half-Life: Approximately 2 hours (systemic); clinical duration 4-6 hours in dogs and cats.

Bioavailability: Inhalation: 1-2% systemic bioavailability; oral: <2%

Protein Binding: Low (less than 10%)

Available Formulations & Strengths

Metered-dose inhaler (MDI) 20 mcg/puff, 40 mcg/puff (Inhalation)

Nebulizer solution 0.02% (0.2 mg/mL), 0.03% (0.3 mg/mL) (Inhalation (nebulization))

Nasal spray (human) 0.03%, 0.06% (Intranasal (not commonly used in veterinary medicine))

Contraindications & Clinical Warnings

Contraindications:

Known hypersensitivity to ipratropium bromide or atropine-like drugs
History of narrow-angle glaucoma (may precipitate angle closure)
Urinary retention or bladder outlet obstruction
Tachyarrhythmias (use with caution)
Concurrent use with other anticholinergics may increase systemic effects

Warnings & Clinical Precautions:

Use with caution in animals with glaucoma, prostatic hypertrophy, or urinary retention
May cause paradoxical bronchospasm in some animals; discontinue if occurs
Not for acute relief of severe bronchospasm; use with a fast-acting beta-agonist
Inhalation may cause coughing or irritation; use with a spacer to improve delivery
Avoid contact with eyes; may cause blurred vision or mydriasis
Use in pregnant or lactating animals only if clearly needed; safety not established
In food animals, observe withdrawal times; extra-label use requires veterinary oversight

Adverse Effects & Reactions

Common:

Cough
Dry mouth
Mild tachycardia
Nasal dryness or irritation

Serious / Severe:

Paradoxical bronchospasm
Urinary retention
Worsening of glaucoma
Cardiac arrhythmias (rare)

Rare:

Hypersensitivity reactions (urticaria, angioedema)
Central nervous system effects (agitation, confusion) at high systemic doses

Key Drug Interactions

Interacting Drug / Class	Clinical Effect & Mechanism	Severity
Other anticholinergic drugs (e.g., atropine, glycopyrrolate)	Additive anticholinergic effects, increased risk of systemic toxicity	Moderate
Beta-agonists (e.g., albuterol, salmeterol)	Additive bronchodilation; may increase risk of tachycardia	Mild
Corticosteroids (inhaled or systemic)	No significant interaction; often used concurrently for synergistic effect	Mild
Digoxin	Increased risk of arrhythmias due to anticholinergic effects on heart rate	Moderate

Overdose & Toxicity Management

Signs of Toxicity:

Tachycardia
Dry mouth
Mydriasis
Urinary retention
Ileus
Agitation or confusion
Hypertension or hypotension

Emergency Treatment Protocol: Treatment is symptomatic and supportive. Since systemic absorption is low, severe toxicity is rare. If overdose occurs, discontinue the drug, monitor vital signs, and provide supportive care. For severe anticholinergic effects, physostigmine may be considered (but use with caution). Administer fluids and manage arrhythmias if needed.

Food Animal Withdrawal Times

🥩 Meat: 0 days🥛 Milk: 0 days🥚 Eggs: 0 days

Ipratropium bromide is not approved for food animals. Withdrawal times are not established. Extra-label use in food animals requires veterinary oversight and extended withdrawal periods should be considered. Consult FARAD (Food Animal Residue Avoidance Databank) for current recommendations.

Storage, Handling & Regulatory Information

Storage Temperature: Store at room temperature (20-25°C, 68-77°F); protect from freezing

Light Sensitivity: Light-sensitive — protect from direct exposure.

Handling & Special Conditions: Keep container tightly closed. Protect from light. Do not puncture or incinerate aerosol canisters. Store away from heat and open flame.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Not FDA-approved for veterinary use; approved for human use (e.g., Atrovent).

Extra-Label (Off-Label) Use: In the US, ipratropium bromide is not FDA-approved for veterinary use. Its use in animals is extra-label and must comply with AMDUCA (Animal Medicinal Drug Use Clarification Act). For food animals, a valid veterinary-client-patient relationship is required, and withdrawal times must be extended. In the EU, similar regulations apply under the cascade.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Ipratropium bromide is a valuable bronchodilator in veterinary medicine, particularly for cats with asthma and dogs with chronic bronchitis. It is often used as an adjunct to beta-agonists and corticosteroids. Because it has a slower onset than beta-agonists, it is not suitable for acute rescue therapy. Inhalation delivery is preferred to minimize systemic side effects. Use with a spacer and mask for small animals. In horses, it is useful for managing heaves. Always monitor for adverse effects, especially in animals with cardiovascular disease. For food animals, extra-label use requires careful consideration of withdrawal times.

References & Literature

📚 Plumb's Veterinary Drug Handbook
📚 Papich Veterinary Pharmacology and Therapeutics
📚 Compendium of Veterinary Products (CVP)